Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 172

Similar articles for PubMed (Select 10342818)

1.

Effects of aggressive cholesterol lowering and low-dose anticoagulation on clinical and angiographic outcomes in patients with diabetes: the Post Coronary Artery Bypass Graft Trial.

Hoogwerf BJ, Waness A, Cressman M, Canner J, Campeau L, Domanski M, Geller N, Herd A, Hickey A, Hunninghake DB, Knatterud GL, White C.

Diabetes. 1999 Jun;48(6):1289-94.

PMID:
10342818
2.

Long-term effects on clinical outcomes of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation in the post coronary artery bypass graft trial. Post CABG Investigators.

Knatterud GL, Rosenberg Y, Campeau L, Geller NL, Hunninghake DB, Forman SA, Forrester JS, Gobel FL, Herd JA, Hickey A, Hoogwerf BJ, Terrin ML, White C.

Circulation. 2000 Jul 11;102(2):157-65.

3.

The effect of aggressive and moderate lowering of LDL-cholesterol and low dose anticoagulation on plasma lipids, apolipoproteins and lipoprotein families in post coronary artery bypass graft trial.

Alaupovic P, Fesmire JD, Hunnighake D, Domanski M, Forman S, Knatterud GL, Forrester J, Herd JA, Hoogwerf B, Campeau L, Gobel FL.

Atherosclerosis. 1999 Oct;146(2):369-79.

PMID:
10532693
5.

Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease. A subgroup analysis of the Scandinavian Simvastatin Survival Study (4S)

Pyŏrälä K, Pedersen TR, Kjekshus J, Faergeman O, Olsson AG, Thorgeirsson G.

Diabetes Care. 1997 Apr;20(4):614-20. Erratum in: Diabetes Care 1997 Jun;20(6):1048.

PMID:
9096989
6.

Aggressive cholesterol lowering delays saphenous vein graft atherosclerosis in women, the elderly, and patients with associated risk factors. NHLBI post coronary artery bypass graft clinical trial. Post CABG Trial Investigators.

Campeau L, Hunninghake DB, Knatterud GL, White CW, Domanski M, Forman SA, Forrester JS, Geller NL, Gobel FL, Herd JA, Hoogwerf BJ, Rosenberg Y.

Circulation. 1999 Jun 29;99(25):3241-7.

7.

Pleiotropic effect of lovastatin, with and without cholestyramine, in the post coronary artery bypass graft (Post CABG) trial.

Domanski M, Tian X, Fleg J, Coady S, Gosen C, Kirby R, Sachdev V, Knatterud G, Braunwald E.

Am J Cardiol. 2008 Oct 15;102(8):1023-7. doi: 10.1016/j.amjcard.2008.05.053. Epub 2008 Aug 9.

PMID:
18929703
9.

Impact of diabetes on 12-month outcomes following coronary artery bypass graft surgery: results from the ROSETTA-CABG Registry.

Gitman MR, Okrainec K, Nguyen H, Duerr R, Del Core M, Fourchy D, Huynh T, Lader E, Rogers FJ, Chaudry MR, Pilote L, Eisenberg MJ; ROSETTA-CABG Investigators.

Can J Cardiol. 2005 Nov;21(13):1169-74.

PMID:
16308592
10.

Effect of an aggressive lipid-lowering strategy on progression of atherosclerosis in the left main coronary artery from patients in the post coronary artery bypass graft trial.

White CW, Gobel FL, Campeau L, Knatterud GL, Forman SA, Forrester JS, Geller NL, Herd JA, Hickey A, Hoogwerf BJ, Hunninghake DB, Rosenberg Y, Terrin ML; Post Coronary Artery Bypass Graft Trial Investigators.

Circulation. 2001 Nov 27;104(22):2660-5.

12.

Quality of life after coronary artery bypass graft: results from the POST CABG Trial.

Fox NL, Hoogwerf BJ, Czajkowski S, Lindquist R, Dupuis G, Herd JA, Campeau L, Hickey A, Barton FB, Terrin ML; POST CABG Study Investigators.

Chest. 2004 Aug;126(2):487-95.

PMID:
15302735
13.

The benefit of aggressive lipid lowering.

Brown WV.

Atheroscler Suppl. 2000 Sep;1(1):15-9. Review.

PMID:
11285716
14.

The relationship between obesity and atherosclerotic progression and prognosis among patients with coronary artery bypass grafts the effect of aggressive statin therapy.

Wee CC, Girotra S, Weinstein AR, Mittleman MA, Mukamal KJ.

J Am Coll Cardiol. 2008 Aug 19;52(8):620-5. doi: 10.1016/j.jacc.2008.05.021.

15.

Comparative effects of 10-mg versus 80-mg Atorvastatin on high-sensitivity C-reactive protein in patients with stable coronary artery disease: results of the CAP (Comparative Atorvastatin Pleiotropic effects) study.

Bonnet J, McPherson R, Tedgui A, Simoneau D, Nozza A, Martineau P, Davignon J; CAP Investigators.

Clin Ther. 2008 Dec;30(12):2298-313. doi: 10.1016/j.clinthera.2008.12.023.

PMID:
19167589
16.

Prognostic factors for atherosclerosis progression in saphenous vein grafts: the postcoronary artery bypass graft (Post-CABG) trial. Post-CABG Trial Investigators.

Domanski MJ, Borkowf CB, Campeau L, Knatterud GL, White C, Hoogwerf B, Rosenberg Y, Geller NL.

J Am Coll Cardiol. 2000 Nov 15;36(6):1877-83.

PMID:
11092659
17.
18.

Effects of aggressive versus moderate glycemic control on clinical outcomes in diabetic coronary artery bypass graft patients.

Lazar HL, McDonnell MM, Chipkin S, Fitzgerald C, Bliss C, Cabral H.

Ann Surg. 2011 Sep;254(3):458-63; discussion 463-4. doi: 10.1097/SLA.0b013e31822c5d78.

PMID:
21865944
19.
20.

The effect of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation on obstructive changes in saphenous-vein coronary-artery bypass grafts.

Post Coronary Artery Bypass Graft Trial Investigators.

N Engl J Med. 1997 Jan 16;336(3):153-62. Erratum in: N Engl J Med 1997 Dec 18;337(25):1859.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk